Protara’s cell therapy touts BCG-naïve treatment potential in Phase II
If TARA-002 reached the market, it would become the first drug to gain approval in the BCG-naïve setting.
Cytiva Navigating cell therapy WP 4
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints
Imugene announces Phase Ib azer-cel efficacy data
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
Zhongmou Therapeutics’ RP gene therapy shows promise in first-in-human trial
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs
Enlivex’s allogeneic cell therapy benefit continues at six months
Sarepta terminates Hansa-partnered gene therapy combination trial
